Breast Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

Published on : Jul-2017 | List of Tables : 185 | List of Figures : 69 | No. of Pages : 170 | Report Code : FACT55MR | Format :

Breast cancer is a cancer that develops when cells and tissues in the breast begin to grow out of control. Usually forming into a tumor, breast cancer is visible as a lump surrounding the internal breast tissues. Breast cancer tumor is malignant, and occurs almost entirely in women, apart from exceptional occurrences in men.

Fact.MR, in its latest report, estimates the global breast cancer diagnostics market to register a moderate expansion at 4.7% CAGR during the forecast period 2017 to 2022.

Screening Practices of Breast Cancer Witnessed to Alter Early Detection Practices

Breast cancer has become the most common type of cancer for women across the globe. The number of women suffering from breast cancer is witnessing a surge. This has led towards necessity for efficient early detection of breast cancer. Mammography screening, an established method adopted across several countries, has been recently been observed to offer inconclusive test results. Risk-adapted, personalized therapy and screening are predicted to resolve these difficulties. In addition, tomosynthesis, a new imaging technology, has been seen to overcome the drawbacks of mammography.

Screening options for breast cancer have been witnessing a rise, and have been altering practices of early detection across industrialized economies. Moreover, countries such as Brazil, India and China are focusing on development of cost-effective screening strategies capable of being adapted as per requirements.

Market Taxonomy

Test Type

End User

BRCA

Hospital Associated Labs

ER & PR

Independent Diagnostic Laboratories

CEA

Cancer Research Institutes

KRAS Mutation

Others

HER 2

 

PSA

 

CA Test

 

EGFR Mutation Test

 

Immunohistochemistry

 

Others

 

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Introduction of Hybrid Imaging Instruments Offering Enhanced Accuracy to Drive Growth of the Market

The global breast cancer diagnostics market has been witnessing a robust transformation on the back of several technological advancements in the diagnostic platforms. The market has witnessed the introduction of hybrid imaging instruments which offer an enhanced accuracy. These advancements have been augmenting growth of the global breast cancer diagnostics market. Increasing incidences of breast cancer and growth in older female population are expected to create lucrative growth opportunities for breast cancer diagnostics. In contrast, shortage of skilled and trained personnel is expected to pose a major challenge to the market growth of breast cancer diagnostics.

By test type, BRCA is expected to remain dominant in the market, with sales poised to surpass US$ 500 Mn by 2022-end. CA test for breast cancer are expected to exhibit the highest CAGR in the market through 2022, followed by ER & PR test. However, revenue from CA, and ER & PR tests will remain low during the forecast period. HER 2 test will remain the second largest test type segment in the global breast cancer diagnostics market. Revenue from EGFR mutation test will continue to be low in the global breast cancer diagnostics market.

Hospital-associated Labs to Remain the Largest End-Users in Breast Cancer Diagnostics Market

Hospital-associated labs are expected to remain the largest end-users of breast cancer diagnostics in the global market. Breast cancer diagnostics in hospital-associated labs will account for the largest revenues by 2022-end, followed by independent diagnostic laboratories. Cancer research institutes are expected to register the highest CAGR through 2022.

Competition Tracking

Key market players mentioned in Fact.MR’s report include Abbott Laboratories, Roche Holding AG, Thermo Fischer Scientific, Inc., Siemens AG, Bio-Rad Laboratories, Inc., Illumina, Inc., Biocept, Inc., Epigenomics AG, AstraZeneca plc, Myriad Genetics, Inc., and Quest Diagnostics Incorporated.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for breast cancer. Rising number of deaths caused by breast cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of breast cancer. For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo. The burden of controlling the incidence of breast cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.

The report on the global market for breast cancer discusses such key factors that govern the economics of breast cancer diagnostics across the globe. Some of the key influences for the growth of global breast cancer diagnostics market include:

  • rising presence of carcinogenic elements in common consumables
  • surging exposure to toxic substances in factories & industrial settings
  • lack of awareness related to causes, symptoms, and preventive measures for breast cancer
  • high healthcare costs, deterring breast cancer patients from seeking optimum diagnosis

With growing incidence of breast cancer, the future generations will witness a more accessible, affordable, and diagnosis-associated treatment for breast cancer. As breast cancer research organizations & societies struggle to develop effective medications in tight-budgeted capitals, governments are deploying initiatives that boost the awareness of breast cancer.

Need for Premeditated Breast Cancer Patient Compliance 

Breast cancer patients are often riddled with confusing options for diagnosis. Choosing the right screening test can become a dilemma for the patient and his/her family. Companies manufacturing medical instruments and devices for diagnosis of breast cancer are expected to mitigate such difficulties by facilitating a well-laid patient compliance regime.

The global market for breast cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings. Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of breast cancer patients.

Key players in the global breast cancer diagnostics market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on breast cancer patients. Such cooperative efforts are of paramount importance in the global breast cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.

Breast Cancer diagnostics market – Regional Overview & Competitive Backdrop

A comprehensive section on the regional analysis of global breast cancer diagnostics market is included in the report. North America, Europe, Japan, Asia-Pacific excluding Japan (APEJ), Latin America, and Middle East & Africa are key regions into which the expansion of global breast cancer diagnostics market is studied. Developed markets with robust healthcare infrastructures are deemed lucrative for patients seeking diagnosis for breast cancer. On the other hand, higher resource availability, cheap wages, and lenient manufacturing regulations in developing regions attract the attention of manufacturers of breast cancer diagnosis instruments.

In the report, there is an elaborate section on the competitive landscape of global breast cancer diagnostics market. This part profiles key players in the global market, which includes leading manufacturers of diagnostic devices and related medical apparatus. The scalability employed in profiling these players includes criteria such as the company’s contribution to global breast cancer diagnostics market revenues, recent mergers & acquisitions involving the company, and new product launches. Through this report, companies can also understand the investment standpoint in the global breast cancer diagnostics market, which can be further inferred while taking insightful actions.

Research Methodology

Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,

  • Primary research
  • Secondary research
  • Trade research
  • Focused interviews
  • Social media analysis

Chapter 1 Global Breast Cancer Diagnostics Market - Executive Summary 19

Chapter 2 Global Breast Cancer Diagnostics Market Overview 21
2.1 Introduction 21
    2.1.1 Global Breast Cancer Diagnostics Market Taxonomy 21
    2.1.2 Global Breast Cancer Diagnostics Market Definition 21
2.2 Global Breast Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022 22
    2.2.1 Global Breast Cancer Diagnostics Market Y-o-Y Growth 22
2.3 Global Breast Cancer Diagnostics Market Dynamics 22
    2.3.1 Drivers 22
    2.3.2 Restraints 22
    2.3.3 Trends 23
2.4 Supply Chain 23
2.5 Epidemiology 23
2.6 List of Distributors 23
2.7 Average Pricing Analysis 23
2.8 Regulations 24
2.9 Key Participants Market Presence (Intensity Map) By Region 24

Chapter 3 Global Breast Cancer Diagnostics Market Analysis and Forecast By Test Type 25
3.1 Global Breast Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022 25
    3.1.1 BRCA Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 25
          3.1.1.1 Revenue (US$ Mn) Comparison, By Region 25
          3.1.1.2 Market Share Comparison, By Region 26
          3.1.1.3 Y-o-Y growth Comparison, By Region 27
    3.1.2 ER & PR Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 28
          3.1.2.1 Revenue (US$ Mn) Comparison, By Region 28
          3.1.2.2 Market Share Comparison, By Region 29
          3.1.2.3 Y-o-Y growth Comparison, By Region 30
    3.1.3 CEA Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 31
          3.1.3.1 Revenue (US$ Mn) Comparison, By Region 31
          3.1.3.2 Market Share Comparison, By Region 32
          3.1.3.3 Y-o-Y growth Comparison, By Region 33
    3.1.4 KRAS Mutation Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 34
          3.1.4.1 Revenue (US$ Mn) Comparison, By Region 34
          3.1.4.2 Market Share Comparison, By Region 35
          3.1.4.3 Y-o-Y growth Comparison, By Region 36
    3.1.5 HER 2 Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 37
          3.1.5.1 Revenue (US$ Mn) Comparison, By Region 37
          3.1.5.2 Market Share Comparison, By Region 38
          3.1.5.3 Y-o-Y growth Comparison, By Region 39
    3.1.6 PSA Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 40
          3.1.6.1 Revenue (US$ Mn) Comparison, By Region 40
          3.1.6.2 Market Share Comparison, By Region 41
          3.1.6.3 Y-o-Y growth Comparison, By Region 42
    3.1.7 CA Test Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 43
          3.1.7.1 Revenue (US$ Mn) Comparison, By Region 43
          3.1.7.2 Market Share Comparison, By Region 44
          3.1.7.3 Y-o-Y growth Comparison, By Region 45
    3.1.8 EGFR Mutation Test Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 46
          3.1.8.1 Revenue (US$ Mn) Comparison, By Region 46
          3.1.8.2 Market Share Comparison, By Region 47
          3.1.8.3 Y-o-Y growth Comparison, By Region 48
    3.1.9 Immunohistochemistry Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 49
          3.1.9.1 Revenue (US$ Mn) Comparison, By Region 49
          3.1.9.2 Market Share Comparison, By Region 50
          3.1.9.3 Y-o-Y growth Comparison, By Region 51
    3.1.10 Others Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 52
          3.1.10.1 Revenue (US$ Mn) Comparison, By Region 52
          3.1.10.2 Market Share Comparison, By Region 53
          3.1.10.3 Y-o-Y growth Comparison, By Region 54

Chapter 4 Global Breast Cancer Diagnostics Market Analysis and Forecast By End User 55
4.1 Global Breast Cancer Diagnostics Market Size and Forecast By End User, 2012-2022 55
    4.1.1 Hospital Associated Labs Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 55
          4.1.1.1 Revenue (US$ Mn) Comparison, By Region 55
          4.1.1.2 Market Share Comparison, By Region 57
          4.1.1.3 Y-o-Y growth Comparison, By Region 57
    4.1.2 Independent Diagnostic Laboratories Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 58
          4.1.2.1 Revenue (US$ Mn) Comparison, By Region 58
          4.1.2.2 Market Share Comparison, By Region 60
          4.1.2.3 Y-o-Y growth Comparison, By Region 60
    4.1.3 Cancer Research Institutes Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 61
          4.1.3.1 Revenue (US$ Mn) Comparison, By Region 61
          4.1.3.2 Market Share Comparison, By Region 63
          4.1.3.3 Y-o-Y growth Comparison, By Region 63
    4.1.4 Others Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 64
          4.1.4.1 Revenue (US$ Mn) Comparison, By Region 64
          4.1.4.2 Market Share Comparison, By Region 66
          4.1.4.3 Y-o-Y growth Comparison, By Region 66

Chapter 5 Global Breast Cancer Diagnostics Market Analysis and Forecast By Region 68
5.1 Global Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 68
    5.1.1 North America Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 68
          5.1.1.1 Revenue (US$ Mn) Comparison, By Test Type 68
          5.1.1.2 Revenue (US$ Mn) Comparison, By End User 70
    5.1.2 Latin America Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 72
          5.1.2.1 Revenue (US$ Mn) Comparison, By Test Type 72
          5.1.2.2 Revenue (US$ Mn) Comparison, By End User 74
    5.1.3 Europe Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 76
          5.1.3.1 Revenue (US$ Mn) Comparison, By Test Type 76
          5.1.3.2 Revenue (US$ Mn) Comparison, By End User 78
    5.1.4 Japan Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 80
          5.1.4.1 Revenue (US$ Mn) Comparison, By Test Type 80
          5.1.4.2 Revenue (US$ Mn) Comparison, By End User 82
    5.1.5 APEJ Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 84
          5.1.5.1 Revenue (US$ Mn) Comparison, By Test Type 84
          5.1.5.2 Revenue (US$ Mn) Comparison, By End User 86
    5.1.6 MEA Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 88
          5.1.6.1 Revenue (US$ Mn) Comparison, By Test Type 88
          5.1.6.2 Revenue (US$ Mn) Comparison, By End User 90

Chapter 6 North America Breast Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022 92
6.1 US Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 92
    6.1.1 Revenue (US$ Mn) Comparison, By Test Type 92
    6.1.2 Revenue (US$ Mn) Comparison, By End User 93
6.2 Canada Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 94
    6.2.1 Revenue (US$ Mn) Comparison, By Test Type 94
    6.2.2 Revenue (US$ Mn) Comparison, By End User 95

Chapter 7 Latin America Breast Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022 96
7.1 Brazil Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 96
    7.1.1 Revenue (US$ Mn) Comparison, By Test Type 96
    7.1.2 Revenue (US$ Mn) Comparison, By End User 97
7.2 Mexico Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 98
    7.2.1 Revenue (US$ Mn) Comparison, By Test Type 98
    7.2.2 Revenue (US$ Mn) Comparison, By End User 99
7.3 Argentina Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 100
    7.3.1 Revenue (US$ Mn) Comparison, By Test Type 100
    7.3.2 Revenue (US$ Mn) Comparison, By End User 101

Chapter 8 Europe Breast Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022 102
8.1 Germany Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 102
    8.1.1 Revenue (US$ Mn) Comparison, By Test Type 102
    8.1.2 Revenue (US$ Mn) Comparison, By End User 103
8.2 UK Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 104
    8.2.1 Revenue (US$ Mn) Comparison, By Test Type 104
    8.2.2 Revenue (US$ Mn) Comparison, By End User 105
8.3 France Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 106
    8.3.1 Revenue (US$ Mn) Comparison, By Test Type 106
    8.3.2 Revenue (US$ Mn) Comparison, By End User 107
8.4 Spain Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 108
    8.4.1 Revenue (US$ Mn) Comparison, By Test Type 108
    8.4.2 Revenue (US$ Mn) Comparison, By End User 109
8.5 Italy Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 110
    8.5.1 Revenue (US$ Mn) Comparison, By Test Type 110
    8.5.2 Revenue (US$ Mn) Comparison, By End User 111
8.6 Nordic Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 112
    8.6.1 Revenue (US$ Mn) Comparison, By Test Type 112
    8.6.2 Revenue (US$ Mn) Comparison, By End User 113

Chapter 9 Japan Breast Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022 114
9.1 Japan Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 114
    9.1.1 Revenue (US$ Mn) Comparison, By Test Type 114
    9.1.2 Revenue (US$ Mn) Comparison, By End User 115

Chapter 10 APEJ Breast Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022 116
10.1 China Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 116
    10.1.1 Revenue (US$ Mn) Comparison, By Test Type 116
    10.1.2 Revenue (US$ Mn) Comparison, By End User 117
10.2 India Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 118
    10.2.1 Revenue (US$ Mn) Comparison, By Test Type 118
    10.2.2 Revenue (US$ Mn) Comparison, By End User 119
10.3 Malaysia Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 120
    10.3.1 Revenue (US$ Mn) Comparison, By Test Type 120
    10.3.2 Revenue (US$ Mn) Comparison, By End User 121
10.4 Thailand Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 122
    10.4.1 Revenue (US$ Mn) Comparison, By Test Type 122
    10.4.2 Revenue (US$ Mn) Comparison, By End User 123
10.5 Singapore Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 124
    10.5.1 Revenue (US$ Mn) Comparison, By Test Type 124
    10.5.2 Revenue (US$ Mn) Comparison, By End User 125
10.6 Australia Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 126
    10.6.1 Revenue (US$ Mn) Comparison, By Test Type 126
    10.6.2 Revenue (US$ Mn) Comparison, By End User 127

Chapter 11 MEA Breast Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022 128
11.1 GCC Countries Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 128
    11.1.1 Revenue (US$ Mn) Comparison, By Test Type 128
    11.1.2 Revenue (US$ Mn) Comparison, By End User 129
11.2 South Africa Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 130
    11.2.1 Revenue (US$ Mn) Comparison, By Test Type 130
    11.2.2 Revenue (US$ Mn) Comparison, By End User 131
11.3 Nigeria Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 132
    11.3.1 Revenue (US$ Mn) Comparison, By Test Type 132
    11.3.2 Revenue (US$ Mn) Comparison, By End User 133
11.4 Israel Breast Cancer Diagnostics Market Size and Forecast, 2012-2022 134
    11.4.1 Revenue (US$ Mn) Comparison, By Test Type 134
    11.4.2 Revenue (US$ Mn) Comparison, By End User 135

Chapter 12 Company Profiles 136
12.1 Abbott Laboratories 136
    12.1.1 Company Overview 136
    12.1.2 Product Overview: 136
    12.1.3 Key Financials: 137
    12.1.4 SWOT Analysis 137
    12.1.5 Key Developments 137
12.2 Roche Holding AG. 138
    12.2.1 Company Overview 138
    12.2.2 Product Overview: 138
    12.2.3 Key Financials: 139
    12.2.4 Key Developments 139
12.3 Thermo Fisher Scientific Inc. 142
    12.3.1 Company Overview 142
    12.3.2 Product Overview: 142
    12.3.3 Key Financials: 143
    12.3.4 SWOT Analysis 143
    12.3.5 Key Developments 143
12.4 Siemens AG 144
    12.4.1 Company Overview 144
    12.4.2 Product Overview: 144
    12.4.3 Key Financials: 145
    12.4.4 SWOT Analysis 145
    12.4.5 Key Developments 145
12.5 Bio-Rad Laboratories, Inc. 146
    12.5.1 Company Overview 146
    12.5.2 Product Overview: 146
    12.5.3 SWOT Analysis 147
    12.5.4 Key Developments 149
12.6 Illumina, Inc. 150
    12.6.1 Company Overview 150
    12.6.2 Product Overview: 150
    12.6.3 Key Financials: 151
    12.6.4 SWOT Analysis 151
12.6.5 Key Development 151
12.7 Biocept, Inc. 152
    12.7.1 Company Overview 152
    12.7.2 Product Overview: 152
    12.7.3 Key Financials 153
    12.7.4 Key Developments 153
12.8 AstraZeneCA plc 154
    12.8.1 Company Overview 154
    12.8.2 Product Overview: 154
    12.8.3 Key Financials 154
    12.8.4 Key Developments 154
    12.8.5 SWOT Analysis 155
12.9 Myriad Genetics Inc 159
    12.9.1 Company Overview 159
    12.9.2 Product Overview 159
    12.9.3 Key Financials 160
    12.9.4 SWOT Analysis 160
12.10 Quest Diagnostics Incorporated 164
    12.10.1 Company Overview 164
    12.10.2 Product Overview 164
    12.10.3 Key Financials 165
    12.10.4 SWOT Analysis 165

Chapter 13 Disclaimer and Contact information 168

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Breast Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022